18 criteria for choosing GSK's Cervarix
This article was originally published in Scrip
Executive Summary
For those wondering how the department of health chose between GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil for the UK's cervical cancer vaccine campaign (Scrip No 3373, p 1), health minister Dawn Primarolo has listed in a recent parliamentary answer the 18 criteria that were used. As well as the obvious clinical and cost reasons, the criteria include pallet configuration, the robustness of manufacturing contingency arrangements, the risk of wastage if subjected to temperatures above 8°C, and the closeness of delivery schedules to requirements.